BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Imaoka H, Shimizu Y, Senda Y, Natsume S, Mizuno N, Hara K, Hijioka S, Hieda N, Tajika M, Tanaka T, Ishihara M, Niwa Y, Yamao K. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Pancreatology 2016;16:658-64. [PMID: 27178104 DOI: 10.1016/j.pan.2016.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Ann Surg Oncol. 2018;25:3483-3491. [PMID: 29786131 DOI: 10.1245/s10434-018-6521-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
2 Wang M, Hu M, Hu B, Guo C, Song Y, Jia Q, He L, Zhang Z, Fang S. Bimetallic cerium and ferric oxides nanoparticles embedded within mesoporous carbon matrix: Electrochemical immunosensor for sensitive detection of carbohydrate antigen 19-9. Biosens Bioelectron 2019;135:22-9. [PMID: 30991268 DOI: 10.1016/j.bios.2019.04.018] [Cited by in Crossref: 99] [Cited by in F6Publishing: 27] [Article Influence: 33.0] [Reference Citation Analysis]
3 Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T, Ishihara M, Hirayama Y, Hieda N, Yoshida T, Okuno N, Shimizu Y, Niwa Y, Yamao K. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Pancreatology. 2016;16:859-864. [PMID: 27256641 DOI: 10.1016/j.pan.2016.05.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
4 van Manen L, Groen JV, Putter H, Pichler M, Vahrmeijer AL, Bonsing BA, Mieog JSD. Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center Study and Meta-Analysis. Cancers (Basel) 2020;12:E2970. [PMID: 33066393 DOI: 10.3390/cancers12102970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Zumpano R, Polli F, D’agostino C, Antiochia R, Favero G, Mazzei F. Nanostructure-Based Electrochemical Immunosensors as Diagnostic Tools. Electrochem 2021;2:10-28. [DOI: 10.3390/electrochem2010002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, Kleiß M, Leha A, Ghadimi M, Gaedcke J. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep 2020;10:1332. [PMID: 31992753 DOI: 10.1038/s41598-020-57930-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
7 Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, Ishikawa H, Kakizawa N, Saito M, Futsuhara K, Noda H, Konishi F, Rikiyama T. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients. Sci Rep 2021;11:20797. [PMID: 34675229 DOI: 10.1038/s41598-021-00060-9] [Reference Citation Analysis]
8 Song JY, Chen MQ, Guo JH, Lian SF, Xu BH. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients. Medicine (Baltimore). 2018;97:e9707. [PMID: 29369199 DOI: 10.1097/md.0000000000009707] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? Int J Mol Sci 2021;22:6413. [PMID: 34203923 DOI: 10.3390/ijms22126413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Quoc Lam B, Shrivastava SK, Shrivastava A, Shankar S, Srivastava RK. The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives. J Cell Mol Med 2020;24:7706-16. [PMID: 32458441 DOI: 10.1111/jcmm.15413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ren H, Wu CR, Aimaiti S, Wang CF. Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma. Oncol Lett 2020;19:4093-105. [PMID: 32382348 DOI: 10.3892/ol.2020.11495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 2021;1875:188409. [PMID: 32827580 DOI: 10.1016/j.bbcan.2020.188409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
13 Shi G, Zhang J, Lu Z, Liu D, Wu Y, Wu P, Yin J, Yuan H, Zhu Q, Chen L, Fu Y, Peng Y, Wang Y, Jiang K, Miao Y. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Oncotarget 2017;8:110849-60. [PMID: 29340021 DOI: 10.18632/oncotarget.22861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
14 Kang YM, Wang H, Li R, Pan G. Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis. Technol Cancer Res Treat 2021;20:15330338211043030. [PMID: 34617852 DOI: 10.1177/15330338211043030] [Reference Citation Analysis]
15 Yang X, Wei Y, Du Y, Qi H, Gao Q, Zhang C. Electrogenerated Chemiluminescence Immunoassays on Nanoelectrode Ensembles Platform with Magnetic Microbeads for the Determination of Carbohydrate Antigen. Anal Chem 2020;92:15837-44. [PMID: 33269595 DOI: 10.1021/acs.analchem.0c03047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Shi S, Yu X. Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 2019;46:39-47. [PMID: 30611527 DOI: 10.1053/j.seminoncol.2018.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Huang Z, Jiang Z, Zhao C, Han W, Lin L, Liu A, Weng S, Lin X. Simple and effective label-free electrochemical immunoassay for carbohydrate antigen 19-9 based on polythionine-Au composites as enhanced sensing signals for detecting different clinical samples. Int J Nanomedicine 2017;12:3049-58. [PMID: 28450781 DOI: 10.2147/IJN.S131805] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
18 Lehtomäki K, Mustonen H, Kellokumpu-Lehtinen PL, Joensuu H, Hermunen K, Soveri LM, Boisen MK, Dehlendorff C, Johansen JS, Haglund C, Osterlund P. Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer. Cancers (Basel) 2021;13:3892. [PMID: 34359796 DOI: 10.3390/cancers13153892] [Reference Citation Analysis]
19 Li J, Chen Q, Jin B, Shi Y, Wu X, Xu H, Zheng Y, Wang Y, Du S, Lu X, Mao Y, Sang X. Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center. Cancer Manag Res 2020;12:411-7. [PMID: 32021453 DOI: 10.2147/CMAR.S229329] [Reference Citation Analysis]
20 Mukerjee S, Gonzalez-Reymundez A, Lunt SY, Vazquez AI. DNA Methylation and Gene Expression with Clinical Covariates Explain Variation in Aggressiveness and Survival of Pancreatic Cancer Patients. Cancer Invest 2020;38:502-6. [PMID: 32935594 DOI: 10.1080/07357907.2020.1812079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]